Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


06.11.2017

1 Am J Gastroenterol
1 Arch Virol
1 BMJ
2 Clin Infect Dis
1 Eur J Gastroenterol Hepatol
1 Gastroenterology
3 Hepatology
1 J Clin Gastroenterol
6 J Hepatol
3 J Med Virol
19 J Viral Hepat
2 J Virol
1 JAMA
2 Lancet Gastroenterol Hepatol
2 Lancet Glob Health
1 MMWR Morb Mortal Wkly Rep
7 PLoS One
2 Vaccine
2 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Gastroenterol

  1. WU T, Kwok RM, Tran TT
    Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.
    Am J Gastroenterol. 2017 Oct 31. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available


    Arch Virol

  2. DE MIRANDA BKB, de Sa KSG, da Silva ANR, Feitosa RNM, et al
    GBV-C/HIV-1 coinfection is associated with low HIV-1 viral load and high CD4+ T lymphocyte count.
    Arch Virol. 2017;162:3431-3438.
    PubMed     Text format     Abstract available


    BMJ

  3. WISE J
    MSF pushes down price of generic hepatitis C drugs to new low level.
    BMJ. 2017;359:j5054.
    PubMed     Text format    


    Clin Infect Dis

  4. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available

  5. YAYA I, Costa M, Marcellin F, Miailhes P, et al
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


    Eur J Gastroenterol Hepatol

  6. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Text format     Abstract available


    Gastroenterology

  7. RATTAY T, Dumont P, Heinzow HS, Hutton DW, et al
    Cost-effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Gastroenterology. 2017 Oct 23. pii: S0016-5085(17)36275.
    PubMed     Text format     Abstract available


    Hepatology

  8. LIU J
    Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Hepatology. 2017 Oct 28. doi: 10.1002/hep.29620.
    PubMed     Text format    

  9. GAO Y, Feng J, Yang G, Zhang S, et al
    HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29316.
    PubMed     Text format     Abstract available

  10. PURI P, Liangpunsakul S, Christensen JE, Shah VH, et al
    The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.
    Hepatology. 2017 Oct 30. doi: 10.1002/hep.29623.
    PubMed     Text format     Abstract available


    J Clin Gastroenterol

  11. ANGULO-DIAZ V, Lim JK, Martin P, Liapakis A, et al
    Management of Chronic Hepatitis C in End-stage Renal Disease.
    J Clin Gastroenterol. 2017 Nov 2. doi: 10.1097/MCG.0000000000000941.
    PubMed     Text format     Abstract available


    J Hepatol

  12. MUELLER H, Wildum S, Luangsay S, Walther J, et al
    A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393.
    PubMed     Text format     Abstract available

  13. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    PubMed     Text format    

  14. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    PubMed     Text format     Abstract available

  15. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    PubMed     Text format     Abstract available

  16. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    PubMed     Text format    

  17. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    PubMed     Text format    


    J Med Virol

  18. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Text format     Abstract available

  19. MEZGEBO TA, Niguse S, Kahsay AG, Hailekiros H, et al
    HEPATITIS B VIRUS INFECTION AND ASSOCIATED RISK FACTORS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN HEALTH FACILITIES OF TIGRAY, NORTHERN ETHIOPIA.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24987.
    PubMed     Text format     Abstract available

  20. KIM DY, Lee HW, Song JE, Kim BK, et al
    Switching from Tenofovir and Nucleoside Analogue Therapy to Tenofovir Monotherapy in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24986.
    PubMed     Text format     Abstract available


    J Viral Hepat

  21. YI W, Li MH, Xie Y, Wu J, et al
    Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2017;24 Suppl 1:49-56.
    PubMed     Text format     Abstract available

  22. REN H
    The experience of management of chronic hepatitis B in China.
    J Viral Hepat. 2017;24 Suppl 1:4-5.
    PubMed     Text format     Abstract available

  23. LUO XD, Chen XF, Zhou Y, Chen XP, et al
    Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNalpha-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    J Viral Hepat. 2017;24 Suppl 1:36-42.
    PubMed     Text format     Abstract available

  24. PAN HY, Pan HY, Song WY, Zheng W, et al
    Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    J Viral Hepat. 2017;24 Suppl 1:29-35.
    PubMed     Text format     Abstract available

  25. LIU J, Chen T, Zhao Y
    Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
    J Viral Hepat. 2017;24 Suppl 1:6-11.
    PubMed     Text format     Abstract available

  26. FOSTER G
    Editorial for "Supplement on Optimal Therapy for Chronic Hepatitis B in China".
    J Viral Hepat. 2017;24 Suppl 1:3.
    PubMed     Text format    

  27. LI SY, Li H, Xiong YL, Liu F, et al
    Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.
    J Viral Hepat. 2017;24 Suppl 1:12-20.
    PubMed     Text format     Abstract available

  28. HUANG D, Sansas B, Jiang JH, Gong QM, et al
    Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
    J Viral Hepat. 2017;24 Suppl 1:66-74.
    PubMed     Text format     Abstract available

  29. SHANG J, Wen Q, Wang CC, Liu K, et al
    Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
    J Viral Hepat. 2017;24 Suppl 1:43-48.
    PubMed     Text format     Abstract available

  30. WANG ML, Chen EQ, Zhang DM, Du LY, et al
    Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    J Viral Hepat. 2017;24 Suppl 1:21-28.
    PubMed     Text format     Abstract available

  31. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    PubMed     Text format     Abstract available

  32. CHOI HY, Kim Y, Cho H, Kim BH, et al
    Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
    PubMed     Text format     Abstract available

  33. MA N, Zhang X, Yang L, Zhou J, et al
    Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12817.
    PubMed     Text format     Abstract available

  34. LIANG X, Xie Q, Tan D, Ning Q, et al
    Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12814.
    PubMed     Text format     Abstract available

  35. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    PubMed     Text format     Abstract available

  36. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    PubMed     Text format     Abstract available

  37. CANNIZZO ES, Tincati C, Binda F, Ronzi P, et al
    Unconventional T-cells in Chronic Hepatitis B Patients on Long-Term Suppressive Therapy with Tenofovir followed by a Peg-IFN Add-On Strategy: a randomized study.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12820.
    PubMed     Text format     Abstract available

  38. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    PubMed     Text format     Abstract available

  39. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    PubMed     Text format     Abstract available


    J Virol

  40. MORENO-CUBERO E, Subira D, Sanz-de-Villalobos E, Parra-Cid T, et al
    According to HCV infection stage, IL-7 plus 4-1BB triggering alone or combined with PD-1 blockade increases TRAF1low HCV-specific CD8+ cell reactivity.
    J Virol. 2017 Nov 1. pii: JVI.01443-17. doi: 10.1128/JVI.01443.
    PubMed     Text format     Abstract available

  41. ZHOU T, Ren X, Adams RL, Pyle AM, et al
    NS3 from HCV strain JFH-1 is an unusually robust helicase that is primed to bind and unwind viral RNA.
    J Virol. 2017 Oct 25. pii: JVI.01253-17. doi: 10.1128/JVI.01253.
    PubMed     Text format     Abstract available


    JAMA

  42. LINDER KA, Malani PN
    Hepatitis A.
    JAMA. 2017 Nov 1. doi: 10.1001/jama.2017.17244.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  43. FURLOW B
    Large hepatitis A outbreaks in USA constrain vaccine supply.
    Lancet Gastroenterol Hepatol. 2017 Oct 24. pii: S2468-1253(17)30329.
    PubMed     Text format    

  44. GORE C, Hicks J, Deelder W
    Funding the elimination of viral hepatitis: donors needed.
    Lancet Gastroenterol Hepatol. 2017 Oct 31. pii: S2468-1253(17)30333.
    PubMed     Text format    


    Lancet Glob Health

  45. DEGENHARDT L, Peacock A, Colledge S, Leung J, et al
    Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Lancet Glob Health. 2017 Oct 23. pii: S2214-109X(17)30375.
    PubMed     Text format     Abstract available

  46. LARNEY S, Peacock A, Leung J, Colledge S, et al
    Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Lancet Glob Health. 2017 Oct 23. pii: S2214-109X(17)30373.
    PubMed     Text format     Abstract available


    MMWR Morb Mortal Wkly Rep

  47. WATTS T, Stockman L, Martin J, Guilfoyle S, et al
    Increased Risk for Mother-to-Infant Transmission of Hepatitis C Virus Among Medicaid Recipients - Wisconsin, 2011-2015.
    MMWR Morb Mortal Wkly Rep. 2017;66:1136-1139.
    PubMed     Text format     Abstract available


    PLoS One

  48. KONDILI LA, Gaeta GB, Brunetto MR, Di Leo A, et al
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    PLoS One. 2017;12:e0185728.
    PubMed     Text format     Abstract available

  49. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Text format     Abstract available

  50. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    PubMed     Text format     Abstract available

  51. HARFOUCHE M, Chemaitelly H, Kouyoumjian SP, Mahmud S, et al
    Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.
    PLoS One. 2017;12:e0187177.
    PubMed     Text format     Abstract available

  52. DULTZ G, Graubard BI, Martin P, Welker MW, et al
    Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.
    PLoS One. 2017;12:e0186898.
    PubMed     Text format     Abstract available

  53. OKA S, Furukawa H, Yasunami M, Kawasaki A, et al
    HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4/DR8 heterozygous genotype.
    PLoS One. 2017;12:e0187325.
    PubMed     Text format     Abstract available

  54. PALIWAL D, Joshi P, Panda SK
    Hepatitis E Virus (HEV) egress: Role of BST2 (Tetherin) and interferon induced long non- coding RNA (lncRNA) BISPR.
    PLoS One. 2017;12:e0187334.
    PubMed     Text format     Abstract available


    Vaccine

  55. LU Y, Zhu FC, Liu JX, Zhai XJ, et al
    The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31428.
    PubMed     Text format     Abstract available

  56. LANDI A, Law J, Hockman D, Logan M, et al
    Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31480.
    PubMed     Text format     Abstract available


    Virology

  57. NAKANO T, Takahashi M, Takahashi K, Nagashima S, et al
    Hepatitis E virus subtype 3f strains isolated from Japanese hepatitis patients with no history of travel to endemic areas - The origin analyzed by molecular evolution.
    Virology. 2017;513:146-152.
    PubMed     Text format     Abstract available

  58. ELIZALDE MM, Sevic I, Gonzalez Lopez Ledesma MM, Campos RH, et al
    Human hepatocytes apoptosis induced by replication of hepatitis B virus subgenotypes F1b and F4: Role of basal core promoter and preCore mutations.
    Virology. 2017;513:160-167.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: